IRCT2013112913932N2
Completed
未知
Comparision of maintenance therapy and continuous intravenous therapy with magnesium sulfate in preterm labor pain management at 24-36 weeks gestation: a randomized controlled trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hormozgan University of Medical Sciences
- Enrollment
- 70
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •gestational age of 24 \- 36 weeks;the presence of atleast 4 uterus contraction during 20 min; dilatation below 4 cm; effacement less than 80%
- •Exclusion criteria:coexistense of medical disease such as diabetes mellitus; asthma; cardiovascular disease; preeclampsia; uterine bleeding; rupture of membrane; placenta decolman; intruterine infections; UTI; fetus anomalies; previous preterm labor pain; lack of decreasing uterus contractions during 2 first hr after administration of magnesium sulfate; The patient need to administration of magnesium sulfate after 24 h.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-NephritisEUCTR2007-000443-99-DEniversitätsklinikum Ulm
Active, not recruiting
Phase 1
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’slymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL(Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma,marginal zone lymphoma), according to the WHO classificationsystem.MedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000013103Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-023407-95-DEF. Hoffmann-La Roche Ltd700
Active, not recruiting
Phase 1
A randomized study comparing maintenance therapy withsubcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system, or other not further classified low malignant lymphoma by immunohistochemistry.MedDRA version: 14.1Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-023407-95-ITROCHE692
Active, not recruiting
Phase 1
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.EUCTR2010-023407-95-ATF. Hoffmann-La Roche Ltd700
Active, not recruiting
Phase 1
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system.MedDRA version: 20.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 100000013103Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-023407-95-GBF. Hoffmann-La Roche Ltd692